|
The following stocks are the leading risers and fallers among London Main Market small-caps on Tuesday. ---------- SMALL-CAP - WINNERS ---------- Hemogenyx Pharmaceuticals PLC, up 12% at 1,021.00 pence, 12-month range 124.00p-1,800.00p. Raises £2.5 million through a direct subscription by private investors to support the continuation of its phase I clinical trials. Hemogenyx issues 313,333 new shares at £7.50 each, with investors also receiving three-year warrants exercisable at £9 per share. The net proceeds are primarily earmarked to fund ongoing phase I trials of its CAR-T therapy HG-CT-1 for relapsed or refractory acute myeloid leukaemia, in both adults and paediatric patients. The company says the fundraise follows a positive recommendation from the independent Data Safety Monitoring Board to continue dose escalation in adults, alongside US Food & Drug Administration clearance to begin a phase I trial in patients aged 12 to 18 years. CEO Vladislav Sandler says: ‘Following the positive recommendation from the DSMB to continue the adult trial at the next dose level and the receipt of FDA clearance to initiate the paediatric study, the Company remains focused on executing its clinical programme. In parallel, we have implemented measures to reduce operating costs, including outsourcing the manufacture of HG-CT-1 to a specialised third-party provider.’ ---------- capAI PLC, up 10% at 1.13p, 12-month range 0.35p-9.38p. Reports a conditional £252,500 fundraise at 1.0p per share to support development and early-stage commercialisation across its capMedical and capMedia platforms. The company focused on artificial intelligence systems for media and medicine says the placing and subscription include £40,000 of director participation, with proceeds earmarked for platform development, partnership structuring and working capital. capAI says capMedical is developing tiered longevity and preventative health programmes priced between $500 and $15,000 per user, subject to ongoing licensing discussions, while capMedia expands its publishing pipeline via the Author42 platform, which is generating initial revenues. The company says it continues to operate a capital-light model, with no obligation to complete platform acquisitions, maintaining strategic flexibility as it assesses scalable, margin-accretive opportunities across its verticals. Executive Chair Ronjon Nag says: ‘Our initial focus within capMedical reflects demand for preventative and longevity-oriented healthcare solutions, while our progress across capMedia highlights how shared platforms and scalable intellectual property can support multiple, complementary routes to value over time. I am particularly enthused by our inaugural concept within capMedical. While there is a broad range of products already available in the market, we believe our potential competitive edge lies in offering a more comprehensive and consolidated approach to ageing, spanning brain, metabolic, cardiovascular, skin and facial, and immune system health, relative to solutions that are either more fragmented or consolidated but less comprehensive in scope.’ ---------- SMALL-CAP - LOSERS ---------- Altona Rare Earths PLC, down 4.8% at 1.96p, 12-month range 1.05p-2.76p. The Africa-focused resource exploration and development company raises £450,000 in cash through the exercise of 30 million warrants at 1.5p per share, with proceeds to fund a fluorspar and gallium resource estimate and scoping study. Altona also issues 2.0 million new shares at 1.0p after its remaining lender elects to convert £20,000 of interest on outstanding debt into equity. CEO Cedric Simonet says: ‘I am pleased to see the increasing market recognition of the value within Altona’s portfolio and strategy, and I am grateful for our existing shareholders’ support as we continue delivering on this strategy.’ ---------- Copyright 2026 Alliance News Ltd. All Rights Reserved.
|
